Business Wire

Lightbits Grows Revenues By Over 5X in 2020 While Driving Innovation Through Technology Advancements and Patents

2.2.2021 16:00:00 EET | Business Wire | Press release

Share

Lightbits Labs, the pioneer and leader in NVMe™ over TCP (NVMe/TCP) software-defined storage, increased sales by more than 500 percent through a significant uptick in infrastructure as a service (IaaS), software as a service (SaaS), financial services, and video gaming customers.

Sales growth was fueled in part by the company’s strong partnerships, to which Intel was added in late September and also included new funding from Intel Capital. The partnership is designed to propel development of disaggregated storage solutions to solve the challenges of today’s data center operators who are craving improved storage efficiency and capacity utilization while maintaining compatibility with existing infrastructure without compromising performance and simplicity. This strategic partnership includes technical co-engineering, go-to-market collaboration, as well as the financial investment.

“In so many ways and for so many people 2020 was a very difficult year. Lightbits is fortunate that we were able to keep our employees safe through remote work, while also achieving and exceeding our goals for the year – including growing our customer base, enhancing our products, and expanding our partnerships and investors,” said Eran Kerzner, CEO. “We fully anticipate a strong surge in our sales throughout 2021.”

Last year, Lightbits announced significant product advancements, introducing LightOS™ 2.0 in June enabling full cloud-native persistent storage with high availability. The technological innovation solidified the company's position as a leader in scalable and efficient cloud-native storage that’s easy to consume for customers' private, hybrid, and edge cloud deployments. In December, the company released LightOS™ 2.1 that further enhances high-performance, scalability, and low latency so Lightbits’ customers can unleash hyperscale storage, but at a fraction of the cost of even the most advanced cloud storage offerings. As an example, Lightbits’ LightOS outperforms even the latest Amazon EBS io2 Block Express volumes with 5 times lower latency (200µs), 6 times the IOPS per volume (1.5M), twice the throughput per volume (8GB/s), 4 times larger volume size (256TB), and has features such as resizable volumes and multi-attach that are still roadmap items for io2 Block Express.

Through these advancements, Lightbits expanded the use cases for its patented solutions, including NVMe as a Service, as part of the IaaS umbrella. For financial services, use cases expanded to include database acceleration and Monte Carlo simulation. And under the SaaS umbrella, Lightbits LightOS gained traction as a high-performance replacement for Ceph.

In addition, Lightbits applied for five new patents that were accepted by the U.S. Patent Office, bringing the number of patents held by Lightbits to 20. The newly minted patents improve key functions within the NVMe/TCP storage architecture and help Lightbits protect its innovative approach to improving storage capacity utilization, reducing latency, and improving garbage collection features.

“With its blend of performance and high availability based around industry standards, NVMe/TCP offers a compelling value proposition for those needing extremely high performance in the composable block storage market,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies Group at IDC Research. “Lightbits Labs has significantly contributed to the NVMe/TCP standard and is continuing to improve upon the standard with its latest IP.”

Details on the new and existing Lightbits Labs patents can be found in the links below:

Among the milestones, 2020 drove several notable industry recognitions including:

Additional Resources:

About Lightbits Labs™

Lightbits Labs’ mission is to lead the cloud-native data center transformation by delivering scalable and efficient software defined storage that is easy to consume. Founded in 2016, Lightbits brings the agility of hyperscale storage to private clouds and edge clouds. The company pioneered NVMe/TCP so the solution is easy to deploy at scale, while delivering performance that is similar to local flash. Lightbits Labs is backed by strategic investors including Cisco Investments, Dell Technologies Capital, Intel Capital, and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital.

Visit www.lightbitslabs.com or contact us at info@lightbitslabs.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Alan Ryan
pr@lightbitslabs.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye